Literature DB >> 25844556

Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy.

Michela Ripolone1, Dario Ronchi2, Raffaella Violano1, Dionis Vallejo3, Gigliola Fagiolari1, Emanuele Barca4, Valeria Lucchini1, Irene Colombo1, Luisa Villa1, Angela Berardinelli5, Umberto Balottin5, Lucia Morandi6, Marina Mora6, Andreina Bordoni2, Francesco Fortunato2, Stefania Corti2, Daniela Parisi7, Antonio Toscano7, Monica Sciacco1, Salvatore DiMauro4, Giacomo P Comi2, Maurizio Moggio1.   

Abstract

IMPORTANCE: The important depletion of mitochondrial DNA (mtDNA) and the general depression of mitochondrial respiratory chain complex levels (including complex II) have been confirmed, implying an increasing paucity of mitochondria in the muscle from patients with types I, II, and III spinal muscular atrophy (SMA-I, -II, and -III, respectively).
OBJECTIVE: To investigate mitochondrial dysfunction in a large series of muscle biopsy samples from patients with SMA. DESIGN, SETTING, AND PARTICIPANTS: We studied quadriceps muscle samples from 24 patients with genetically documented SMA and paraspinal muscle samples from 3 patients with SMA-II undergoing surgery for scoliosis correction. Postmortem muscle samples were obtained from 1 additional patient. Age-matched controls consisted of muscle biopsy specimens from healthy children aged 1 to 3 years who had undergone analysis for suspected myopathy. Analyses were performed at the Neuromuscular Unit, Istituto di Ricovero e Cura a Carattere Scientifico Foundation Ca' Granda Ospedale Maggiore Policlinico-Milano, from April 2011 through January 2015. EXPOSURES: We used histochemical, biochemical, and molecular techniques to examine the muscle samples. MAIN OUTCOMES AND MEASURES: Respiratory chain activity and mitochondrial content.
RESULTS: Results of histochemical analysis revealed that cytochrome-c oxidase (COX) deficiency was more evident in muscle samples from patients with SMA-I and SMA-II. Residual activities for complexes I, II, and IV in muscles from patients with SMA-I were 41%, 27%, and 30%, respectively, compared with control samples (P < .005). Muscle mtDNA content and cytrate synthase activity were also reduced in all 3 SMA types (P < .05). We linked these alterations to downregulation of peroxisome proliferator-activated receptor coactivator 1α, the transcriptional activators nuclear respiratory factor 1 and nuclear respiratory factor 2, mitochondrial transcription factor A, and their downstream targets, implying depression of the entire mitochondrial biogenesis. Results of Western blot analysis confirmed the reduced levels of the respiratory chain subunits that included mitochondrially encoded COX1 (47.5%; P = .004), COX2 (32.4%; P < .001), COX4 (26.6%; P < .001), and succinate dehydrogenase complex subunit A (65.8%; P = .03) as well as the structural outer membrane mitochondrial porin (33.1%; P < .001). Conversely, the levels of expression of 3 myogenic regulatory factors-muscle-specific myogenic factor 5, myoblast determination 1, and myogenin-were higher in muscles from patients with SMA compared with muscles from age-matched controls (P < .05). CONCLUSIONS AND RELEVANCE: Our results strongly support the conclusion that an altered regulation of myogenesis and a downregulated mitochondrial biogenesis contribute to pathologic change in the muscle of patients with SMA. Therapeutic strategies should aim at counteracting these changes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25844556      PMCID: PMC4944827          DOI: 10.1001/jamaneurol.2015.0178

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  62 in total

Review 1.  Macromolecular complexes: SMN--the master assembler.

Authors:  M P Terns; R M Terns
Journal:  Curr Biol       Date:  2001-10-30       Impact factor: 10.834

2.  SMNrp is an essential pre-mRNA splicing factor required for the formation of the mature spliceosome.

Authors:  G Meister; S Hannus; O Plöttner; T Baars; E Hartmann; S Fakan; B Laggerbauer; U Fischer
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

3.  Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype.

Authors:  V Dubowitz
Journal:  Eur J Paediatr Neurol       Date:  1999       Impact factor: 3.140

4.  Mitochondrial biogenesis during skeletal muscle regeneration.

Authors:  Stéphanie Duguez; Léonard Féasson; Christian Denis; Damien Freyssenet
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-04       Impact factor: 4.310

5.  The SMN genes are subject to transcriptional regulation during cellular differentiation.

Authors:  D Germain-Desprez; T Brun; C Rochette; A Semionov; R Rouget; L R Simard
Journal:  Gene       Date:  2001-11-28       Impact factor: 3.688

6.  Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy.

Authors:  Séverine Guettier-Sigrist; Bénédicte Hugel; Gilliane Coupin; Jean-Marie Freyssinet; Philippe Poindron; Jean-Marie Warter
Journal:  Muscle Nerve       Date:  2002-05       Impact factor: 3.217

Review 7.  The SMN complex, an assemblyosome of ribonucleoproteins.

Authors:  Sergey Paushkin; Amélie K Gubitz; Séverine Massenet; Gideon Dreyfuss
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

8.  Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype.

Authors:  V Sossi; A Giuli; T Vitali; F Tiziano; M Mirabella; A Antonelli; G Neri; C Brahe
Journal:  Eur J Hum Genet       Date:  2001-02       Impact factor: 4.246

9.  Cytochrome c oxidase deficiency due to a novel SCO2 mutation mimics Werdnig-Hoffmann disease.

Authors:  Leonardo Salviati; Sabrina Sacconi; Minerva M Rasalan; David F Kronn; Alex Braun; Peter Canoll; Mercy Davidson; Sara Shanske; Eduardo Bonilla; Arthur P Hays; Eric A Schon; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2002-05

10.  Lack of apoptosis in mitochondrial encephalomyopathies.

Authors:  M Sciacco; G Fagiolari; C Lamperti; S Messina; P Bazzi; L Napoli; L Chiveri; A Prelle; G P Comi; N Bresolin; G Scarlato; M Moggio
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

View more
  40 in total

Review 1.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

Review 2.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

3.  Motor neuron mitochondrial dysfunction in spinal muscular atrophy.

Authors:  Nimrod Miller; Han Shi; Aaron S Zelikovich; Yong-Chao Ma
Journal:  Hum Mol Genet       Date:  2016-08-03       Impact factor: 6.150

4.  A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice.

Authors:  Sagit Golko-Perez; Tamar Amit; Orit Bar-Am; Moussa B H Youdim; Orly Weinreb
Journal:  Neurotox Res       Date:  2016-11-08       Impact factor: 3.911

5.  iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases.

Authors:  Chuang-Yu Lin; Michiko Yoshida; Li-Tzu Li; Akihiro Ikenaka; Shiori Oshima; Kazuhiro Nakagawa; Hidetoshi Sakurai; Eriko Matsui; Tatsutoshi Nakahata; Megumu K Saito
Journal:  JCI Insight       Date:  2019-09-19

6.  Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models.

Authors:  Jeong-Ki Kim; Narendra N Jha; Zhihua Feng; Michelle R Faleiro; Claudia A Chiriboga; Lan Wei-Lapierre; Robert T Dirksen; Chien-Ping Ko; Umrao R Monani
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 7.  Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?

Authors:  Chiara Simone; Agnese Ramirez; Monica Bucchia; Paola Rinchetti; Hardy Rideout; Dimitra Papadimitriou; Diane B Re; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2015-12-18       Impact factor: 9.261

8.  Motor neuron biology and disease: A current perspective on infantile-onset spinal muscular atrophy.

Authors:  Narendra N Jha; Jeong-Ki Kim; Umrao R Monani
Journal:  Future Neurol       Date:  2018-07-06

Review 9.  Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

10.  Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy.

Authors:  Gillian K Maxwell; Eva Szunyogova; Hannah K Shorrock; Thomas H Gillingwater; Simon H Parson
Journal:  J Anat       Date:  2018-02-22       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.